BioCorRx to Participate in the Benzinga All Access Event on December 2…
ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of inventive treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will be participating in the Benzinga All Access event taking place on December 2, 2021.
Ms. Felix and Mr. Granier are scheduled to present on December 2, 2021 at 11:00 A.M. Eastern Time.
The event will be broadcast live and can be viewed here. An archived recording of the presentation will be obtainable on the investor relations section of the BioCorRx website at ir.biocorrx.com.
About Benzinga All Access
Benzinga All Access is a first-of-its-kind show: part interview, part investor presentation. On All Access, Benzinga partners with companies to bring you in-thoroughness one-on-one conversations with executives across a wide range of industries and asset classes. From emerging biotechs, to different real estate investment platforms, to everything in between, guests on All Access have one thing in shared: they want to tell their story to investors.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a rare approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer sustain via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-need wellness specialists: nutritionists, fitness experts and personal sustain from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
Safe shelter Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “calculate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements include known and unknown. risks in addition as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may unprotected to may differ materially from any forward-looking statements, which mirror the opinions of the management of the Company only as of the date hereof.
Crescendo Communications, LLC
(212) 671-1020 x304
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.
Click: See details